{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:21:59Z","timestamp":1776943319180,"version":"3.51.4"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.berh.2023.101822","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:35:45Z","timestamp":1678462545000},"page":"101822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis"],"prefix":"10.1016","volume":"36","author":[{"given":"Margaret","family":"Man-Ger Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2023.101822_bib1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/ard.2009.111005","article-title":"Increase in age at onset of giant cell arteritis: a population-based study","volume":"69","author":"Kermani","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/rheumatology\/keg116","article-title":"Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment","volume":"42","author":"Nordborg","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib3","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2023.101822_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.30155","article-title":"The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases","volume":"63","author":"Crowson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/art.1780261007","article-title":"The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee","volume":"26","author":"Smith","year":"1983","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib7","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1093\/rheumatology\/keaa095","article-title":"Incidence and prevalence of giant cell arteritis in Ontario, Canada","volume":"59","author":"Barra","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-021-02450-w","article-title":"A\u00a0meta-analysis of the epidemiology of giant cell arteritis across time and space","volume":"23","author":"Li","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101822_bib9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/acr.24573","article-title":"Increased mortality for individuals with giant cell arteritis: a population-based study","volume":"74","author":"Barra","year":"2022","journal-title":"Arthritis Care Res"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib10","article-title":"All-cause and cause-specific mortality in giant cell arteritis, a population-based study [abstract]","volume":"74","author":"Sode","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonz\u00e1lez-Gay","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101822_bib12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 Years: a population-based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101822_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101822_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4078\/jrd.2014.21.6.297","article-title":"Epidemiology of polymyalgia rheumatica in Korea","volume":"21","author":"Kim","year":"2014","journal-title":"Journal of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2023.101822_bib15","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/acr.24403","article-title":"Mortality among patients with polymyalgia rheumatica: a retrospective cohort study","volume":"73","author":"Partington","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101822_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semarthrit.2003.09.007","article-title":"Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions","volume":"33","author":"Gonzalez-Gay","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib17","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib18","article-title":"Silent giant cell arteritis in patients with polymyalgia rheumatica: characteristics and peculiarities [abstract]","volume":"74","author":"De Miguel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib19","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.3390\/jcm11247412","article-title":"Predictive factors of giant cell arteritis in polymyalgia rheumatica patients","volume":"11","author":"Ramon","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.berh.2023.101822_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MD.0b013e318145275c","article-title":"Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients","volume":"86","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2023.101822_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Narv\u00e1ez","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3899\/jrheum.170455","article-title":"Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study","volume":"45","author":"Liozon","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib23","first-page":"2179","article-title":"The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain","volume":"27","author":"Gonzalez-Gay","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib24","first-page":"1750","article-title":"Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica","volume":"25","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.2003.011692","article-title":"Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study","volume":"63","author":"Moosig","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/acr2.11163","article-title":"The utility of 18F-FDG PET\/CT in patients with clinical suspicion of polymyalgia rheumatica and giant cell arteritis: a prospective, observational, and cross-sectional study","volume":"2","author":"Emamifar","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/s10165-011-0581-x","article-title":"Whole-body fluorodeoxyglucose positron emission tomography\/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis","volume":"22","author":"Yamashita","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/14397595.2015.1071304","article-title":"MMP-3 can distinguish isolated PMR from PMR with GCA: a retrospective study regarding PMR and GCA in Japan","volume":"26","author":"Fukui","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02754-5","article-title":"Angiopoietin-2\/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica","volume":"24","author":"van Sleen","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101822_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2015.02.009","article-title":"A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility","volume":"96","author":"Carmona","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2023.101822_bib31","first-page":"179","article-title":"IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis","volume":"20","author":"Gonzalez-Gay","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib32","first-page":"32","article-title":"Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis","author":"Salvarani","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib33","first-page":"33","article-title":"Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse\/recurrence in polymyalgia rheumatica","author":"Boiardi","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib34","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","article-title":"Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis","volume":"36","author":"Roche","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib35","first-page":"112","article-title":"Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection","volume":"23","author":"Elling","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2023.101822_bib36","first-page":"2624","article-title":"Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection","volume":"30","author":"Peris","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/annrheumdis-2016-210152","article-title":"Infections and the risk of incident giant cell arteritis: a population-based, case-control study","volume":"76","author":"Rhee","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101822_bib38","doi-asserted-by":"crossref","first-page":"14364","DOI":"10.1038\/s41598-019-50892-9","article-title":"Tuberculosis infection in Chinese patients with giant cell arteritis","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"},{"issue":"1 Suppl 44","key":"10.1016\/j.berh.2023.101822_bib39","first-page":"S15","article-title":"The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations","volume":"25","author":"Bas-Lando","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/rheumatology\/kez289","article-title":"Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study","volume":"59","author":"Yates","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.semarthrit.2018.07.001","article-title":"Smoking as a risk factor for giant cell arteritis: a systematic review and meta-analysis","volume":"48","author":"Brennan","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib42","article-title":"Cohort study of cigarette smoking and the risk of developing polymyalgia rheumatica among women [abstract]","volume":"74","author":"Kang","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib43","first-page":"753","article-title":"Giant cell arteritis and vascular disease\u2014risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink","volume":"56","author":"Li","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib44","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2013-204167","article-title":"Performance of the new 2012 EULAR\/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study","volume":"73","author":"Macchioni","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"Provisional classification criteria for polymyalgia rheumatica: a European League against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"Provisional classification criteria for polymyalgia rheumatica: a European League against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib47","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/keab506","article-title":"Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR\/ACR provisional classification criteria for polymyalgia rheumatica","volume":"61","author":"Kobayashi","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/kex411","article-title":"Fusion of positron emission tomography\/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica","volume":"57","author":"Owen","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib49","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/rheumatology\/ket229","article-title":"High frequency of capsular knee involvement in polymyalgia rheumatica\/giant cell arteritis patients studied by positron emission tomography","volume":"52","author":"Cimmino","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3899\/jrheum.151103","article-title":"Assessment of the new 2012 EULAR\/ACR clinical classification criteria for polymyalgia rheumatica: a prospective multicenter study","volume":"43","author":"Ozen","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/1756-185X.13923","article-title":"Diagnostic performance of the 2012 EULAR\/ACR classification criteria for polymyalgia rheumatica in Korean patients","volume":"23","author":"Lee","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib52","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2023.101822_bib53","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","article-title":"Disease pattern in cranial and large-vessel giant cell arteritis - PubMed","volume":"42","author":"Brack","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMcp1214825","article-title":"Giant-cell arteritis and polymyalgia rheumatica","volume":"371","author":"Weyand","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2023.101822_bib56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/acr.24393","article-title":"Association between specimen length and number of sections and diagnostic yield of temporal artery biopsy for giant cell arteritis","volume":"73","author":"Muratore","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101822_bib57","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib58","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1093\/rheumatology\/keaa102","article-title":"Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis","volume":"59","author":"Hop","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib59","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.39333","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European league against rheumatism\/American college of rheumatology collaborative initiative","volume":"67","author":"Dejaco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib60","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib61","article-title":"Treatment of polymyalgia rheumatica by rheumatology providers: results from the ACR rheumatology informatics system for effectiveness registry [abstract]","volume":"74","author":"Sattui","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101822_bib97","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2023.101822_bib98","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.berh.2023.101822_bib99","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101822_bib100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.berh.2023.101822_bib101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2023.101822_bib102","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib62","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A\u00a0disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib63","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101822_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2023.101822_bib65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-020-02377-8","article-title":"Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations","volume":"23","author":"Unizony","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101822_bib66","first-page":"112","article-title":"Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice","volume":"38","author":"Calder\u00f3n-Goercke","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib67","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/annrheumdis-2022-eular.4027","article-title":"POS0817 Tocilizumab in newly diagnosed giant cell arteritis versus refractory\/recurrent giant cell arteritis; multicenter study of 471 patients of clinical practice","volume":"81","author":"Sanchez-Martin","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib68","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib69","article-title":"Long-term efficacy of tocilizumab monotherapy after ultra-short glucocorticoid administration to treat giant cell arteritis \u2013 one year follow-up of the GUSTO trial","volume":"74","author":"Christ","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2022-eular.2096","article-title":"OP0185 Tocilizumab in combination with 8 weeks of prednisone for giant cell arteritis","volume":"81","author":"Unizony","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2023.101822_bib71","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","article-title":"A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatology and Therapy"},{"key":"10.1016\/j.berh.2023.101822_bib72","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib73","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib74","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000162","article-title":"Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases","volume":"1","author":"Izumi","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101822_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101822_bib77","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2023.101822_bib78","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizuamb in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib79","article-title":"Effectiveness of interleukin-6 receptor inhibitors for polymyalgia rheumatica [abstract]","volume":"74","author":"Curtis","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib85","first-page":"17","article-title":"Biologic therapies for giant cell arteritis","volume":"15","author":"Harrington","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.berh.2023.101822_bib80","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2022-eular.5004a","article-title":"LB0006 Sarilumab in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR)","volume":"81","author":"Dasgupta","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib81","article-title":"Resolution of PMR signs and symptoms in patients treated with sarilumab: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR) in relapsing PMR","volume":"74","author":"Spiera","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib82","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): a prospective study","volume":"74","author":"Ma","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib83","doi-asserted-by":"crossref","unstructured":"Zhang L., Li J., Yin H., et\u00a0al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study. Annals of the Rheumatic Diseases Published Online First: 05 January 2023. doi: 10.1136\/ard-2022-223562.","DOI":"10.1136\/ard-2022-223562"},{"key":"10.1016\/j.berh.2023.101822_bib84","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib86","article-title":"Ustekinumab for the treatment of giant cell arteritis published online ahead of print, 2020 Apr 5","author":"Matza","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101822_bib87","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib88","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.berh.2023.101822_bib89","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo-controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib91","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/annrheumdis-2021-eular.1623","article-title":"POS0338 Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments","volume":"80","author":"Deshayes","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101822_bib92","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101822_bib93","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s13063-021-05520-1","article-title":"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial","volume":"22","author":"Venhoff","year":"2021","journal-title":"Trials"},{"issue":"suppl 9","key":"10.1016\/j.berh.2023.101822_bib94","article-title":"Secukinumab in giant cell arteritis: a randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial [abstract]","volume":"73","author":"Venhoff","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101822_bib95","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"11","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatology"},{"key":"10.1016\/j.berh.2023.101822_bib96","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/annrheumdis-2022-eular.1797","article-title":"POS0269 Results of one year observational extension of the bridge-pmr study, a randomized double-blind placebo controlled trial with rituximab in polymyalgia rheumatica","volume":"81","author":"Bolhuis","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:15Z","timestamp":1761499395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521694223000086"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101822","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101822"}}